SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-113132
Filing Date
2020-10-07
Accepted
2020-10-07 17:28:29
Documents
12
Period of Report
2020-10-02
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2032672-1_8k.htm   iXBRL 8-K 26822
  Complete submission text file 0001104659-20-113132.txt   202562

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ckpt-20201002.xsd EX-101.SCH 3198
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ckpt-20201002_lab.xml EX-101.LAB 34591
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ckpt-20201002_pre.xml EX-101.PRE 22718
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2032672-1_8k_htm.xml XML 3726
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38128 | Film No.: 201229684
SIC: 2834 Pharmaceutical Preparations